• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Elanco Animal Health (ELAN) Undervalued Following Its FDA Emergency Use Authorization?

    Simply Wall St·08/09/2026 04:43:00
    语音播报

    Elanco Animal Health (ELAN) is back in focus after receiving an Emergency Use Authorization from the U.S. Food and Drug Administration for CLiK Extra wound spray to help prevent New World screwworm infestations in livestock and captive wildlife.

    See our latest analysis for Elanco Animal Health.

    The Emergency Use Authorization comes shortly after Elanco Animal Health reported second quarter revenue of US$1,368 million and higher net income, alongside raised 2026 guidance. However, the stock’s recent momentum has cooled, with the share price down 16.1% over 7 days. Even so, a 1 year total shareholder return of 32.7% and a 3 year total shareholder return of 81.8% still paint a stronger longer term picture.

    If this kind of company specific news has your attention, it can be useful to widen the lens and see how other businesses are priced and performing. A good next step is to scan our screener of 20 top founder-led companies

    Elanco Animal Health now trades well below both analyst targets and an estimate of fair value, even after stronger recent results and new product authorizations. Is this discount a genuine opportunity or a sign the market remains rightly cautious about Elanco’s risks and execution?

    Most Popular Narrative: 25.7% Undervalued

    At a last close of $22.12, the most followed Elanco Animal Health narrative points to a fair value near $29.79, which implies a sizeable valuation gap built on detailed long term forecasts.

    The analysts have a consensus price target of $29.79 for Elanco Animal Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $23.0.

    Read the complete narrative.

    Curious what sits behind that spread of views? The narrative leans on steady revenue expansion, a swing from losses to profits, and a rich future earnings multiple. The mix of growth, margins and discount rate assumptions does the heavy lifting. The interesting part is how much of that journey is baked into one number.

    Result: Fair Value of $29.79 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Elanco Animal Health still faces pressure from foreign exchange swings and higher launch driven operating expenses. These factors could weigh on margins and unsettle the current valuation narrative.

    Find out about the key risks to this Elanco Animal Health narrative.

    Next Steps

    With sentiment around Elanco Animal Health pulled between optimism and caution, it can help to move quickly, test the numbers and stress test the story yourself. To understand why some investors are focused on the upside, start with the 4 key rewards

    Looking for more investment ideas beyond Elanco Animal Health?

    If you like the story around Elanco Animal Health, do not stop here. Fresh ideas often appear where you least expect them, so give yourself options.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.